


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A 3,6-substituted pyran group-containing compound having the structural formula:



wherein


A, A' are each phenyl;

B is optionally substituted C₄-C₁₄ aryl;

Z is a chemical bond;

R is H or C₁₋₈ alkyl;

W is selected from the group consisting of hydrogen and -OH, wherein when H is ~~hydrogen~~
W is hydrogen, B is described by the following formula:



p is 0-6;

R^1 is C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} optionally halogenated alkynyl, C_{2-6} hydroxyalkynyl, -CN, -COOR⁴, -OH, -NO₂, -NH₂, -NHR⁴, -SO₂NH₂, -NHSO₂R⁸, -OCF₃, or -OR⁸;

R^4 is H, C_{1-18} alkyl, C_{5-10} cycloalkyl, or C_{2-18} alkylene


R^8 is C_{1-8} alkyl, C_{5-6} cycloalkyl, C_{2-8} alkenyl, or a 5 or 6-member aromatic ring including heterocyclic rings;

n is 0 ; and

m is 1


or a pharmaceutically acceptable derivative or salt thereof.

2. (Currently Amended) The compound of claim 1, ~~wherein at least one of A and A'~~ are:



where R^1 is selected from the group consisting of C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} optionally halogenated alkynyl, C_{2-6} hydroxyalkynyl, halo, -CN, -COOR, where R is C_{1-18} alkyl, C_{5-10} cycloalkyl, C_{2-18} alkenyl, -OH, -NO₂, -NH₂, -OR² where R^2 is C_{1-8} alkyl, C_{5-6} cycloalkyl, or C_{2-8} alkenyl.


3. (Currently Amended) The compound of claim 1, wherein B is selected from the group



where $R^{1'}$ is selected ~~is selected~~ from the group consisting of C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} optionally halogenated alkynyl, C_{2-6} hydroxyalkynyl, halo, -CN, -COOR, where

R is C₁₋₁₈ alkyl, C₅₋₁₀ cycloalkyl, C₂₋₁₈ alkenyl, -OH, -NO₂, -NH₂, -OR² where R² is C₁₋₈ alkyl, C₅₋₆ cycloalkyl, or C₂₋₈ alkenyl; and wherein R² have the meaning of R^{1'} and also a 5 or 6 membered heterocycle containing 1 or more heteroatoms selected from the group consisting of N, O, and S, and wherein X is N, O, or S.


4. (Previously Presented) The compound of claim 2, wherein B is selected from the group




where R^{1'} is selected from the group consisting of C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ optionally halogenated alkynyl, C₂₋₆ hydroxyalkynyl, halo, -CN, -COOR, where R is C₁₋₁₈ alkyl, C₅₋₁₀ cycloalkyl, C₂₋₁₈ alkenyl, -OH, -NO₂, -NH₂, -OR² where R² is C₁₋₈ alkyl, C₅₋₆ cycloalkyl, or C₂₋₈ alkenyl; and wherein R² have the meaning of R^{1'} and also a 5 or 6 membered heterocycle containing 1 or more heteroatoms selected from the group consisting of N, O, and S, and wherein X is N, O, or S.

5. (Original) The compound of claim 3, wherein A and A' are both unsubstituted phenyl.


6. (Original) The compound of claim 1, having the formula




7. (Original) The compound of claim 2, having the formula




8. (Original) The compound of claim 3, having the formula




9. (Original) The compound of claim 1, having the formula




10. (Original) The compound of claim 2, having the formula




11. (Original) The compound of claim 3, having the formula




12. (Original) The compound of claim 1, having a formula selected from the group consisting of:




13. (Original) The compound of claim 2, having a formula selected from the group consisting of:



14. (Original) The compound of claim 3, having a formula selected from the group consisting of:



15. (Original) The compound of claim 5, having a formula selected from the group consisting of:



16. (Currently Amended) The compound of claim 1, selected from the group consisting of:

Cis-(6-benzhydryl-tetrahydropyran-3-yl)-(4-hydroxy-benzyl)-amine (16h);
Cis-(6-benzhydryl-tetrahydropyran-3-yl)-(1H-iodo-5-ylmethyl)-amine (16n);
Cis-(6-benzhydryl-tetrahydropyran-3-yl)-(4-amino-benzyl)-amine (16o);
Cis-(6-benzhydryl-tetrahydropyran-3-yl)-(3,4-dichloro-benzyl)-amine (16i);
(2S, 4R, 5R)-2-benzhydryl-5-(4-methoxy-benzylamino)-tetrahydropyran-4-ol (-)29a;
(2S, 4R, 5R)-2-benzhydryl-5-(4-fluoro-benzylamino)-tetrahydro-pyran-4-ol (-)29b;
(2S, 4R, 5R)-2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol (-)29d;
(2S, 4R, 5R)-2-benzhydryl-5-(2,4-dimethoxy-benzylamino)-tetrahydropyran-4-ol (-)29e;
(2S, 4R, 5R)-2-benzhydryl-5-(3,5-dimethoxy-benzylamino)-tetrahydropyran-4-ol (-)29f;



(2S, 4R, 5R)-2-benzhydryl-5-(4-hydroxy-benzylamino)-tetrahydropyran-4-ol (-)32a;
(2R, 4S, 5S)-2-benzhydryl-5-(4-hydroxy-benzylamino)-tetrahydro-pyran-4-ol (+)32a;
~~(3S, 6S)-(6-benzhydryl-tetrahydropyran-3-yl)-(4-hydroxy-benzyl)-amine (-)37a; and
cis-(3S, 6S)-(6-benzhydryl-tetrahydropyran-3-yl)-(4-hydroxy-benzyl)-amine (-)37a;~~
and
cis-(3R, 6R)-(6-benzhydryl-tetrahydropyran-3-yl)-(4-hydroxy-benzyl)-amine (+)37a.

17. (Previously Presented) The compound of claim 1, selected from the group consisting of:

(2S, 4R, 5R)-2-benzhydryl-5-(4-methoxy-benzylamino)-tetrahydropyran-4-ol (-)29a;
(2S, 4R, 5R)-2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol (-)29d;
(2S, 4R, 5R)-2-benzhydryl-5-(2,4-dimethoxy-benzylamino)-tetrahydropyran-4-ol (-)29e;
(2S, 4R, 5R)-2-benzhydryl-5-(3,5-dimethoxy-benzylamino)-tetrahydropyran-4-ol (-)29f;
(2S, 4R, 5R)-2-benzhydryl-5-(4-hydroxy-benzylamino)-tetrahydropyran-4-ol (-)32a;
(2R, 4S, 5S)-2-benzhydryl-5-(4-hydroxy-benzylamino)-tetrahydro-pyran-4-ol (+)32a;
cis-(3S, 6S)-(6-benzhydryl-tetrahydropyran-3-yl)-(4-hydroxy-benzyl)-amine (-)37a;
and
cis-(3R, 6R)-(6-benzhydryl-tetrahydropyran-3-yl)-(4-hydroxy-benzyl)-amine (+)37a.

18.-24. (Cancelled)

25. (Currently Amended) A compound having the following formula:



or a pharmaceutically acceptable salt thereof.